NCT00204373View on ClinicalTrials.gov

Treatment of Zollinger-Ellison Syndrome With Prevacid

PHASE4CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Zollinger-Ellison SyndromeMultiple Endocrine Neoplasia
Interventions
DRUG

Lansoprazole (Prevacid)

Lansoprazole 30mg capsules. dose is individualized to each subject based on gastric acid production. The range is 30 mg to 450 mg daily.

All Listed Sponsors
collaborator

Takeda Pharmaceuticals North America, Inc.

INDUSTRY

lead

Charles Mel Wilcox, MD

OTHER

NCT00204373 - Treatment of Zollinger-Ellison Syndrome With Prevacid | Biotech Hunter | Biotech Hunter